SeekingAlpha · Aug 14, 2026
FB
NASDAQ · FBRX
Forte Biosciences, Inc.
Healthcare · Biotechnology
$76.99
Up+$0.00 (+0.00%)
Updated Sep 10, 2026, 8:52 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 284.11M
- P/E ratio
- -7.8
- Dividend yield
- 0.00%
- 52-week range
- $15.51 – $77.20
- Volume
- 1.4M
- Avg. volume
- 102.85K
Price performance
FBRX price history
1M range · 11 trading sessions · Daily adjusted prices
FBRX closed at $76.99 after 11 trading sessions, up 0.27% for the selected period.
- Last close
- $76.99
- Period change
- +0.27%
- Period low
- $76.78
- Period high
- $76.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 26, 2026 | $76.97 | $77.00 | $76.96 | $76.99 | 1.4M |
| Aug 25, 2026 | $76.96 | $76.98 | $76.95 | $76.97 | 1.24M |
| Aug 24, 2026 | $76.94 | $76.95 | $76.92 | $76.95 | 1.26M |
| Aug 21, 2026 | $76.94 | $76.95 | $76.89 | $76.92 | 2.01M |
| Aug 20, 2026 | $76.93 | $76.95 | $76.82 | $76.89 | 3.2M |
| Aug 19, 2026 | $76.89 | $76.945 | $76.87 | $76.90 | 6.48M |
| Aug 18, 2026 | $76.86 | $76.91 | $76.85 | $76.88 | 771.13K |
| Aug 17, 2026 | $76.85 | $76.90 | $76.84 | $76.89 | 558.16K |
| Aug 14, 2026 | $76.86 | $76.87 | $76.82 | $76.83 | 490.26K |
| Aug 13, 2026 | $76.82 | $76.875 | $76.78 | $76.86 | 1.15M |
| Aug 12, 2026 | $76.87 | $76.90 | $76.76 | $76.78 | 1.92M |
Latest FBRX news
The latest Smart Investors Daily articles mentioning FBRX.
Stock researchCompany · Overview
FBRX research
Overview
Company profile and research snapshot.
Company profile
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $65.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 28, 2026 | Barclays | Equal-Weight | — |
| Jul 21, 2026 | Barclays | Overweight | — |
| Nov 25, 2025 | Evercore ISI Group | Outperform | — |
| Nov 17, 2025 | Chardan Capital | Buy | — |
| Aug 18, 2025 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance.
Benzinga · Aug 6, 2026
argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte Biosciences
argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a
Benzinga · Jul 28, 2026
Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77
Barclays analyst Etzer Darout downgrades Forte Biosciences (NASDAQ:FBRX) from Overweight to Equal-Weight and raises the price target from $74 to $77.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
